The Food and Drug Administration (FDA) has approved three GLP-1s for obesity-related treatment, including Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)
Based on the route of administration, the GLP-1 receptor agonist market is classified into parenteral and oral segments
This is simply the reality of a drug still in development
But the study had significant flaws
Whilst, Ex-4 did not modify secretory currents evoked by the cholinergic agonist, carbachol ( n = 6, p = 0.0815, Figure 5B), currents evoked by the Na + channel agonist, veratridine were potentiated ( n = 8, p = 0.0085, Figure 5C)
These injectable treatments, including Mounjaro, are part of a group of drugs originally developed to help people manage type 2 diabetes